USE OF SFRP-3 IN THE ASSESSMENT OF HEART FAILURE

• US 20110027819A1
• Filed: 10/11/2010
• Published: 02/03/2011
• Est. Priority Date: 04/30/2008
• Status: Active Grant

• Current Assignee: The Governing Council of the University of Toronto (University of Toronto)
• Original Assignee: The Governing Council of the University of Toronto (University of Toronto)
• Inventors: Liu, Peter, Wienhues-Thelen, Ursula-Henrike, Arab, Sara, Heudig, Hendrik, MacLennan, David, Hess, Georg, Gramolini, Anthony, Emili, Andrew, Block, Dirk
• Granted Patent: US 8,691,587 B2
• Time in Patent Office: Days
• US Class Current: 435/29
• CPC Class Codes: G01N 2800/325 Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
• CPC Class Codes: G01N 33/566 using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.

Claims

1. A method for assessing heart failure in an individual comprising the steps of

measuring in a sample obtained from the individual a concentration of secreted frizzled related protein 3 (SFRP-3),

optionally measuring in the sample a concentration of an additional marker of heart failure, and

assessing heart failure by comparing the concentration of SFRP-3 determined and optionally the concentration of the additional marker determined to a concentration of SFRP-3 and optionally the additional marker in a control sample, whereby the assessment of heart failure is enabled.

2. The method according to claim 1, wherein the sample is selected from the group consisting of serum, plasma, and whole blood.

3. The method according to claim 1 wherein the additional marker is selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation.

4. The method according to claim 3, wherein the natriuretic peptide marker is N-terminal pro-brain natriuretic peptide (NT-proBNP).

5. The method according to claim 3, wherein the cardiac troponin marker is troponin T.

6. The method according to claim 1, wherein the individual is at risk for heart failure.

7. A kit for performing the method according to claim 1 comprising the reagents required to specifically measure SFRP-3 and optionally the reagents required to specifically measure the additional marker of heart failure.